A Study of Bimagrumab in Participants With HFpEF

ClinicalTrials.gov ID: NCT07920887

Public ClinicalTrials.gov record NCT07920887. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.

Study identification

NCT ID: NCT07920887
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 540 participants

Conditions and interventions

Conditions

Interventions

Bimagrumab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2026 (Estimated)
Primary completion: Jul 2029 (Estimated)
Completion: Nov 2029 (Estimated)
Last update posted: Nov 6, 2026

2026 – 2029

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
InvivoCure LLC	Van Nuys	California	91405	—
Amavita Research Services, LLC	North Miami Beach	Florida	33169	—
Dharma PA d/b/a Southwest Family Medicine Associates	Dallas	Texas	75235	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07920887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2026 · Synced Nov 6, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07920887 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →